Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.70 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
By David Willey, Benzinga 
Via TheNewswire.com
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Why Are Antifungal Focused Scynexis Stock Plunging Today?
Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga 
Via Benzinga
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga
Price Over Earnings Overview: GSK
Via Benzinga
How Is The Market Feeling About GSK?
Via Benzinga
Peering Into GSK's Recent Short Interest
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug
The European Commission has approved ViiV Healthcare's Apretude (cabotegravir long-acting (LA) injectable and tablets)  
Via Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer. 
Via Investor's Business Daily
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by... 
Via Benzinga
Pleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology Deal
FDA has  
Via Benzinga
Exposures Product Safety
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
From GSK plc
Via Business Wire
Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,  
Via Benzinga
Exposures COVID-19
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony. 
Via InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
Exposures Product Safety
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Viatris, GSK, and Organon are all trading at less than 7 times earnings. 
Via The Motley Fool
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
From GSK plc
Via Business Wire
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common. 
Via Benzinga
7 Stocks Hedge Funds Are Loading Up On
Hedge funds and many other financial institutions are loading up on these names considered to be among top institutional stock picks. 
Via InvestorPlace
GSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027
GSK Plc (NYSE: GSK) has made an investment of over €250 million ($272 million) in a vaccine facility located in Belgium. 
Via Benzinga
3 Growth Stocks to Ride the Coming Bull Market in Style
Bull markets always follow bear markets, and these three companies are growth stocks to buy for the next wave higher 
Via InvestorPlace
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
Exposures Product Safety
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
From GSK plc
Via Business Wire
Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors?
GSK offers a robust dividend yield, but that's not the only thing to consider. 
Via The Motley Fool
3 Pharma Stocks to Sell in August Before They Crash and Burn
Stay far away from these pharma stocks that are suffering from declining sales and weak pipelines of future products. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.